News about "Zydus Lifesciences"

Zydus Lifesciences Launches Aerolife Mini, India's First Portable Foldable Spacer

Zydus introduces Aerolife Mini, a compact pMDI enhancer designed to improve inhaler drug delivery and patient compliance in respiratory care through a convenient, foldable design.

Zydus Lifesciences | 20/03/2026 | By News Bureau

Zydus and Torrent Pharma Sign Licensing Deal to Co-Market Semaglutide in India

Zydus Lifesciences and Torrent Pharmaceuticals have entered a licensing agreement to co-market Semaglutide injection in India, aiming to improve access for patients with poorly controlled Type 2 Diabetes Mellitus and support chronic weight management through advanced, innovative therapy.

Zydus Lifesciences | 19/03/2026 | By News Bureau |  109

Lupin and Zydus Partner to Co-Market Semaglutide Injection in India

Lupin has secured semi-exclusive rights to co-market Zydus’ Semaglutide injection in India under the brands Semanext and Livarise, while Zydus will continue marketing it under the brand names SEMAGLYNTM, MASHEMATM and ALTERMETM.

Zydus Lifesciences | 18/03/2026 | By News Bureau

US FDA Approves Zydus' Cevimeline Hydrochloride Capsules 30 mg

Zydus Lifesciences has received USFDA approval for Cevimeline Hydrochloride Capsules 30 mg for treating dry mouth associated with Sjögren’s syndrome. The capsules will be manufactured at the company’s SEZ-II facility in Ahmedabad.

Zydus Lifesciences | 13/03/2026 | By News Bureau

Zydus Gets USFDA Tentative Nod for Dapagliflozin Tablets

Zydus has received tentative approval from the US Food and Drug Administration (USFDA) for dapagliflozin tablets in 5 mg and 10 mg strengths, paving the way for the company’s entry into the US market subject to final approval.

Zydus Lifesciences | 06/02/2026 | By News Bureau |  103

Zydus Launches World's First Nivolumab Biosimilar 'Tishtha' in India

Zydus Lifesciences has launched Tishtha, the world’s first biosimilar of the immunotherapy drug nivolumab, in India, aimed at expanding access to advanced cancer care by offering the treatment at nearly one-fourth the cost of the reference product for patients with multiple cancer types.

Zydus Lifesciences | 23/01/2026 | By News Bureau |  384

Zydus Partners with Bioeq for US Commercialisation of Lucentis Biosimilar

Zydus has entered into a partnership with Bioeq to commercialise NUFYMCO, an interchangeable biosimilar to Lucentis, in the US market. Under the agreement, Bioeq will handle development, manufacturing, regulatory approval and product supply, while Zydus will oversee US commercialisation.

Zydus Lifesciences | 24/12/2025 | By News Bureau |  115

Zydus Lifesciences Inks Exclusive Deal with Myriad Genetics for Cancer Risk Tests in India

Zydus Lifesciences has entered into an exclusive agreement with US-based Myriad Genetics to introduce clinically validated cancer-risk assessment diagnostic tests in India, aimed at enabling personalised, evidence-based cancer care and strengthening early detection and preventive oncology efforts in the country.

Zydus Lifesciences | 19/12/2025 | By News Bureau |  120

Zydus and SIG Sign Deal to Launch Single-Serve Spouted Pouches for Cough and Cold Medication

Zydus Lifesciences is introducing Deriphyllin CoughGo in single-serve spouted pouches utilising SIG’s advanced filling technology.

Zydus Lifesciences | 18/11/2025 | By Dineshwori |  264

Zydus Lifesciences Secures US FDA Approval for Leuprolide Acetate Injection

Zydus Lifesciences has received final approval from the US Food and Drug Administration (FDA) for its generic version of Leuprolide Acetate injection, in a 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial format.

Zydus Lifesciences | 17/11/2025 | By Darshana |  240